Quoted from http://www.reuters.com/article/2013/06/06/us-avandia-fda-idUSBRE9540K120130606
FDA panel votes to relax Avandia restrictions
By David Morgan
WASHINGTON | Thu Jun 6, 2013 6:11pm EDT
WASHINGTON (Reuters) - U.S. health advisers voted on Thursday to recommend relaxing market restrictions on GlaxoSmithKline's diabetes drug Avandia, the former blockbuster at the center of one of the biggest drug controversies in recent years.
The vote, by a divided Food and Drug Administration advisory committee of outside health experts, could modestly enlarge the market for Avandia in the United States and lay the groundwork for further research into the drug's health risks. FDA will now take the vote into consideration for a final decision on how the pill also known by the generic name rosiglitazone can be used.